Bicara Therapeutics
IPO
Fighting cancer with precision and power.
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2020
- Business Model
- B2B
- Website
- bicaratherapeutics.com
- Total Funding
- $313.0M
- Last Round
- $165.0M Series CDec 2023
About
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional biologics that combine tumor-targeting antibodies with tumor microenvironment modulators to treat solid tumors. Its bifunctional antibody platform is designed to deliver immunomodulatory payloads directly to the tumor site, enabling synergistic anti-tumor immune activity. The company is publicly traded (Nasdaq: BCAX) and advancing its lead programs through Phase 1b and Phase 3 clinical trials.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account